The Board of Directors of American Renal Associates Holdings, Inc. (the “Company”) has established December 6, 2019 as the date of the Company’s 2019 Annual Meeting of Stockholders (the “2019 Annual Meeting”). Because the date of the 2019 Annual Meeting has been delayed by more than 30 days from the anniversary date of the Company’s 2018 Annual Meeting of Stockholders, in accordance with Rule 14a-5(f) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Company is informing stockholders of such change. Stockholders of record as of the close of business on October 11, 2019 will be entitled to notice of, and to vote at, the 2019 Annual Meeting. The exact time and location of the 2019 Annual Meeting will be specified in the Company’s proxy statement for the 2019 Annual Meeting.
Stockholders of the Company who wish to have a proposal considered for inclusion in the Company’s proxy materials for the 2019 Annual Meeting to Rule 14a-8 under the Exchange Act must ensure that such proposal is received by the Company’s Secretary at American Renal Associates Holdings, Inc., 500 Cummings Center, Suite 6550, Beverly, MA 01915, on or prior to September 27, 2019, which the Company has determined to be a reasonable time before it expects to begin to publish and send notice of its proxy materials. Any such proposal must also meet the requirements set forth in the rules and regulations of the Securities and Exchange Commission in order to be eligible for inclusion in the proxy materials for the 2019 Annual Meeting.
In addition, our Amended and Restated Bylaws (the “Bylaws”) permit stockholders to nominate candidates for director and present other business for consideration at our annual meeting of stockholders. To make a director nomination or present other business for consideration at the 2019 Annual Meeting, you must submit a timely notice in accordance with the procedures described in the Bylaws. To be timely, a stockholder’s notice must be delivered to the Secretary at our principal executive offices not later than the close of business on September 23, 2019 (the 10th day following the day on which this public announcement of the date of the 2019 Annual Meeting was made). The Bylaws have additional requirements that must also be followed in connection with submitting nominations or other business at an annual meeting.
About American Renal Associates Holdings, Inc. (NYSE:ARA)

American Renal Associates Holdings, Inc. is a dialysis services provider in the United States. The Company focuses on joint venture partnerships with physicians. The Company’s segment is the ownership and operation of dialysis clinics. It provides patient care and clinical outcomes to patients suffering from the advanced stage of chronic kidney disease, known as end stage renal disease (ESRD). It operates clinics through a joint venture (JV) model, in which it partners with local nephrologists to develop, own and operate dialysis clinics. Each of its clinics is maintained as a separate joint venture in which it has the controlling interest, and its nephrologist partners and other joint venture partners have a non-controlling interest. The Company opens over 20 de novo clinics each year. The Company has owned and operated over 190 dialysis clinics in partnership with approximately 350 nephrologist partners treating over 13,000 patients in over 20 states and the District of Columbia.